ARDELYX, INC.
ARDX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ARDX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ARDX
Ardelyx, Inc. is a patient-focused biopharmaceutical company that discovers, develops, and commercializes first-in-class medicines for unmet medical needs, with two marketed products—IBSRELA and XPHOZAH—and a pipeline including tenapanor for chronic idiopathic constipation (CIC) and early-stage programs.
Key risk: High debt burden
BioSniper Score
Based on 6 of 6 signals
Market Cap
$983.7M
Cash Runway
150.3 moLead Asset
IBSRELA (Approved)Next Catalyst
Phase3_Topline · Sep 1, 2026Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 4 clinical trials · 5 catalysts · 2 FDA decisions for ARDELYX, INC..
Similar companies
Ardelyx, Inc. is a patient-focused biopharmaceutical company that discovers, develops, and commercializes first-in-class medicines for unmet medical needs, with two marketed products—IBSRELA and XPHOZAH—and a pipeline including tenapanor for chronic idiopathic constipation (CIC) and early-stage programs.
- Achieved net product sales revenue of $377.8 million in 2025 from IBSRELA ($274.2M) and XPHOZAH ($103.6M), representing 18% year-over-year growth [sec · filed 2026-04-29].
- As of 2026-06-30, the company reported cash & equivalents of $97.2M, total revenue of $120.9M, net income of -$16.7M, shareholders' equity of $166.9M, and total debt of $251.8M [latest reported financials].
- Research and development expenses increased 67% to $26.1M in Q2 2026 versus Q2 2025, driven by external R&D costs for life cycle management initiatives, particularly the CIC program [sec_mda · as of 2026-08-06].
- The company has a loan agreement with SLR Capital Partners, with an interest-only period extended to July 1, 2028, and the ability to draw additional capital [sec · filed 2025-04-30].
What works
- Two approved commercial products (IBSRELA and XPHOZAH) generated $377.8M in net product sales in 2025, with 18% year-over-year growth [sec · filed 2026-04-29].
- The company has a pipeline expansion with tenapanor for CIC (Phase 3 topline expected 2026-09-01) and early-stage preclinical programs [sec_mda · as of 2026-08-06].
- Management has demonstrated cost discipline, with net loss and 2025 ending cash favorable to budget [sec · filed 2026-04-29].
What to weigh
- The company reported a net loss of -$16.7M for the six months ended 2026-06-30, with total debt of $251.8M exceeding shareholders' equity of $166.9M [latest reported financials].
- R&D expenses increased significantly (67% in Q2 2026 vs Q2 2025), driven by clinical trial activities for the CIC program, which may pressure near-term profitability [sec_mda · as of 2026-08-06].
- The company experienced a product timeline setback in 2025, which affected compensation decisions [sec · filed 2026-04-29].
From the filings
Quoted directly from source documents.
2025 net product sales revenue of $377.8 million from IBSRELA and XPHOZAH
“the Company achieved net product sales revenue of $377.8 million through our two commercial products, IBSRELA ® and XPHOZAH ® , representing 18% year-over-year growth.”
SEC filings · April 29, 2026
External R&D costs are substantially for life cycle management of tenapanor, with more than half for CIC program
“External R&D expenses consist substantially of costs associated with our life cycle management initiatives for tenapanor, with more than half of these costs attributable to our CIC program for the three and six months ended June 30, 2026, respectively.”
SEC MD&A · August 6, 2026
Loan agreement with SLR extended interest-only period to July 1, 2028
“we extended the interest-only period for existing and new tranches under the loan agreement until July 1, 2028.”
SEC filings · April 30, 2025
Catalyst timeline
- 2026-09-01 · Phase3_Topline — Phase 3 Topline: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Effi — Topline results from a 12-week Phase 3 study of tenapanor for CIC; positive data could support label expansion.
- 2027-06-04 · Phase3_Topline — Phase 3 Topline: A 26-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and — Topline results from a 26-week Phase 3 study of tenapanor for a second indication; may inform long-term efficacy and safety.
- 2031-10-01 · Phase3_Topline · tenapanor — Phase 3 Topline: An Open-Label Long-Term Safety Study of Tenapanor for the Treatment of Irritable Bowel Syndrome With — Topline results from an open-label long-term safety study of tenapanor for IBS; supports long-term safety profile.
- 2042-11-26 · Patent_Expiry · IBSRELA — Patent/Exclusivity Expiry: IBSRELA — Patent/exclusivity expiry for IBSRELA; potential generic competition thereafter.
- 2042-11-26 · Patent_Expiry · XPHOZAH — Patent/Exclusivity Expiry: XPHOZAH — Patent/exclusivity expiry for XPHOZAH; potential generic competition thereafter.
Risks & what to watch (4)›
Key risks
- High debt burden — Total debt of $251.8M exceeds shareholders' equity of $166.9M as of 2026-06-30 [latest reported financials].
- Net loss and negative profitability — Net income of -$16.7M for the six months ended 2026-06-30, with ongoing R&D spending [latest reported financials].
- Product timeline setback — A product timeline setback occurred in 2025, affecting compensation and potentially delaying pipeline progress [sec · filed 2026-04-29].
- Competitive talent market — Company operates in a highly competitive environment for talented senior executives [sec · filed 2026-04-29].
What to watch
- Phase 3 topline data for tenapanor in CIC expected 2026-09-01 [upcoming catalysts].
- Phase 3 topline data for tenapanor in a second indication expected 2027-06-04 [upcoming catalysts].
- Patent/Exclusivity expiry for IBSRELA and XPHOZAH in 2042-11-26 [upcoming catalysts].
- Cash burn rate and ability to manage debt with $97.2M cash as of 2026-06-30 [latest reported financials].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run ARDELYX, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ARDELYX, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
150.3 months
D/E 2.86 · 0% dilution
Lead: Approved
3 candidates
5 upcoming, next in ~2d
0 buys · 25 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
236
Total value held
$1.09B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 21,164,132 | $126.8M |
| vanguard capital management llc | 20,731,024 | $124.2M |
| millennium management llc | 18,043,970 | $108.1M |
| janus henderson group plc | 16,742,468 | $100.3M |
| state street corp | 13,604,307 | $81.5M |
| nomura asset management international inc. | 8,169,369 | $48.9M |
| vanguard portfolio management llc | 6,661,693 | $39.9M |
| geode capital management, llc | 6,007,455 | $36.0M |
| two sigma investments, lp | 4,274,043 | $25.6M |
| citadel advisors llc | 3,763,774 | $22.5M |
Showing top 10 of 236 institutional holders of ARDELYX, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 9.8%
- Days to cover
- 7.2
- Shares short
- 23,569,074
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ARDX short interestGovernance
Frequently asked questions
What is the AI investment thesis for ARDELYX, INC.?
Ardelyx, Inc. is a patient-focused biopharmaceutical company that discovers, develops, and commercializes first-in-class medicines for unmet medical needs, with two marketed products—IBSRELA and XPHOZAH—and a pipeline including tenapanor for chronic idiopathic constipation (CIC) and early-stage programs.
What is ARDELYX, INC.'s lead drug candidate?
ARDELYX, INC.'s most advanced tracked candidate is IBSRELA (Approved) for Irritable bowel syndrome with constipation (IBS-C) in adults.
What is ARDELYX, INC.'s next catalyst?
ARDELYX, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Effi" — expected September 1, 2026.
Who is the CEO of ARDELYX, INC.?
Mr. Michael G. Raab is the chief executive officer of ARDELYX, INC. (ARDX).
Where is ARDELYX, INC. headquartered?
ARDELYX, INC. (ARDX) is headquartered in Waltham, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.